Comparative Pharmacology
Head-to-head clinical analysis: WEGOVY versus YEZTUGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: WEGOVY versus YEZTUGO.
WEGOVY vs YEZTUGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Semaglutide, a GLP-1 receptor agonist, increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and reduces appetite via central GLP-1 receptor activation.
Yeztugo (tugofinitib) is a selective inhibitor of fibroblast growth factor receptor (FGFR) 1-4. It binds to the ATP-binding pocket of FGFR kinases, blocking downstream signaling pathways (RAS-MAPK, PI3K-AKT, STAT) involved in cell proliferation and survival.
Subcutaneous injection 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly for 4 weeks, then 1 mg once weekly for 4 weeks, then 1.7 mg once weekly for 4 weeks, then maintenance 2.4 mg once weekly.
YEZTUGO is not an approved drug. No standard dosing available.
None Documented
None Documented
Terminal elimination half-life is approximately 1 week (6–8 days), supporting once-weekly subcutaneous dosing.
12-15 hours in healthy adults; prolonged to 24-30 hours in moderate hepatic impairment.
Primarily renal; approximately 97% of the dose is excreted unchanged in urine, with less than 3% in feces via biliary excretion.
Primarily renal (>90% unchanged) with 5-10% biliary/fecal elimination.
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist